Erectile Dysfunction News and Research

Latest Erectile Dysfunction News and Research

Men referred for borderline testosterone levels have much higher rates of depression than general population

Men referred for borderline testosterone levels have much higher rates of depression than general population

Loyola offers holistic approach to help couples manage their sexual health

Loyola offers holistic approach to help couples manage their sexual health

Human breast milk bought online poses serious health risks

Human breast milk bought online poses serious health risks

Study shows 28% decline in prostate cancer diagnoses following USPSTF recommendation against PSA testing

Study shows 28% decline in prostate cancer diagnoses following USPSTF recommendation against PSA testing

Low heart rate variability may place women at risk for sexual dysfunction

Low heart rate variability may place women at risk for sexual dysfunction

Men who use finasteride to treat benign prostate enlargement experience worsening ED

Men who use finasteride to treat benign prostate enlargement experience worsening ED

Can-Fite BioPharma receives Notice of Allowance for patent covering manufacturing method of CF101 drug

Can-Fite BioPharma receives Notice of Allowance for patent covering manufacturing method of CF101 drug

Can-Fite BioPharma reports Q1 2015 financial results, provides updates on drug development programs

Can-Fite BioPharma reports Q1 2015 financial results, provides updates on drug development programs

Endo Pharmaceuticals supports efforts to bring first ever treatment guidelines for Peyronie's Disease

Endo Pharmaceuticals supports efforts to bring first ever treatment guidelines for Peyronie's Disease

Can-Fite receives EMA clearance to begin CF102 Phase II trial for treatment of HCC patients in Europe

Can-Fite receives EMA clearance to begin CF102 Phase II trial for treatment of HCC patients in Europe

Can-Fite announces favorable data from further analysis of CF101 Phase II/III study in patients with psoriasis

Can-Fite announces favorable data from further analysis of CF101 Phase II/III study in patients with psoriasis

Can-Fite seeks EMA Orphan Drug Designation for CF102 in HCC

Can-Fite seeks EMA Orphan Drug Designation for CF102 in HCC

Non-vigorous walking may help prostate cancer survivors reduce damaging side effects

Non-vigorous walking may help prostate cancer survivors reduce damaging side effects

Eisai, Arena complete two Phase 1 registrational trials for once-daily formulation of lorcaserin

Eisai, Arena complete two Phase 1 registrational trials for once-daily formulation of lorcaserin

Study: Viagra, other related drugs not a universal 'cure-all' for impotence

Study: Viagra, other related drugs not a universal 'cure-all' for impotence

Study identifies gut immune system as new, effective target for diabetes

Study identifies gut immune system as new, effective target for diabetes

Loyola takes holistic approach to help couples manage their sexual health

Loyola takes holistic approach to help couples manage their sexual health

Can-Fite BioPharma's CF101Phase II/III psoriasis trial fails to meet primary endpoint

Can-Fite BioPharma's CF101Phase II/III psoriasis trial fails to meet primary endpoint

Researchers evaluate decision aids for patient's choice of localised prostate cancer treatment

Researchers evaluate decision aids for patient's choice of localised prostate cancer treatment

Radiation treatment can be delayed after prostatectomy to prevent side effects, say studies

Radiation treatment can be delayed after prostatectomy to prevent side effects, say studies

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.